FDA Brief

Warning letters Drugs

FDA warning letter to

OrderlyMeds LLC dba OrderlyMeds

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

What happened

In March 2026, FDA reviewed OrderlyMeds' website, orderlymeds.com, and found it offered compounded semaglutide and tirzepatide products. FDA said label images showed OrderlyMeds' logo, suggesting it was the compounder when it was not, and the site said products came from an 'FDA-licensed pharmacy,' a designation FDA does not give to pharmacies or outsourcing facilities. FDA cited these as false or misleading claims that make the drugs misbranded, meaning their labeling is false or misleading.

What FDA found

  1. Website label images show OrderlyMeds' logo, suggesting OrderlyMeds made the compounded drugs when the letter says it does not.

    FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. The website says the compounded products are sourced from an 'FDA-licensed pharmacy,' but FDA does not license pharmacies or outsourcing facilities or approve their compounded drugs.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. These false or misleading claims make the drugs misbranded, and shipping them in interstate commerce is prohibited.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  4. Compounded drugs must meet the conditions in section 503A or 503B to be exempt from certain FD&C Act requirements, including new drug approval.

    FD&C Act §§ 503A, 503B [21 U.S.C. §§ 353a, 353b]

What FDA wants

FDA tells OrderlyMeds to respond in writing within 15 business days to CDER's Office of Compounding Quality and Compliance, explaining corrective steps and how it will prevent recurrence. The response should identify the entities that make the compounded products, include sample labeling, and address or remove other false or misleading website claims.

Who should pay attention

  • telehealth companies marketing compounded semaglutide or tirzepatide
  • compounders whose names or labels appear on seller websites
  • websites that describe suppliers as FDA-approved or FDA-licensed

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low